Follicle Divide: How Age Cohorts Are Redefining Alopecia Treatment Demand in China
Description
China's alopecia market follows an adoption-led growth pattern, shaped by NMPA clearance of new JAK inhibitor therapies and expanding listed hair transplant chain capacity across major cities. Entry-year momentum reflects regulatory and product activity across pharmaceutical and procedural categories. For instance, in March 2023, Eli Lilly, China, secured NMPA approval of Olumiant for severe alopecia areata in adults, the first systemic label indication for the disease in the country. Pfizer followed in October 2023 with NMPA approval of Litfulo for patients aged 12 and above, opening treatment access to adolescents. Sansheng Pharma expanded its Mandi minoxidil franchise with a foam formulation approval, reinforcing distribution across roughly 90,000 retail pharmacies nationwide. These are some of the key factors driving revenue growth of the market.
Table of Contents
28 Pages
- 1 Executive Summary
- 2 Scope & Definitions
- 3 Market Forecast
- 4 Segment Analysis
- 5 Demand Drivers
- 6 Competitive Landscape
- 7 Country Outlook
- 8 Strategic Outlook
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

